| BioXcel Therapeutics, Inc. (BTAI) Reports Q3 Loss, Lags Revenue Estimates | 11/14 09:20 | zacks.com |
| BioXcel Therapeutics, Inc. (BTAI) Q3 2024 Earnings Call Transcript | 11/14 09:07 | seekingalpha.com |
| BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024 | 11/08 07:00 | globenewswire.com |
| Will BioXcel Therapeutics, Inc. (BTAI) Report Negative Q3 Earnings? What You Should Know | 11/05 11:05 | zacks.com |
| BioXcel Therapeutics to Present at ThinkEquity Conference | 10/29 07:00 | globenewswire.com |
| BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder | 10/15 07:00 | globenewswire.com |
| BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation | 09/19 07:00 | globenewswire.com |
| BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia | 09/05 07:00 | globenewswire.com |
| BioXcel Therapeutics (BTAI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now | 08/30 10:56 | zacks.com |
| BioXcel Therapeutics, Inc. (BTAI) Q2 2024 Earnings Call Transcript | 08/09 21:48 | seekingalpha.com |